Category - Developments

Cellectar Biosciences

Cellectar gets NCI grant for PDC platform

Cellectar Biosciences (NASDAQ:CLRB) has received initial notice of award for a Phase I-II Fast-Track Small Business Innovation Research (SBIR) grant. The SBIR grant provides up to $2.3-million over 2 1/2 years from the...

Vital Therapies

Vital outlines plans for new Phase 3 ELAD trial

Vital Therapies (NASDAQ:VTL) has outlined plans for a possible new Phase 3 clinical trial designed to confirm ELAD’s safety and efficacy in alcohol-induced liver decompensation (AILD), including severe acute alcoholic...


Novadaq unveils SPY-Q Case Manager software

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has unveiled its SPY-Q Case Manager (SPY-QCM) software at the Symposium on Advanced Wound Care Fall 2015 meeting in Las Vegas. SPY-QCM is an image acquisition and analysis...

Dipexium Pharmaceuticals

Dipexium presents Locilex data at ICAAC/ICC

Dipexium Pharmaceuticals and research collaborators, JMI Laboratories, have presented new Locilex microbiology data at the American Society for Microbiology’s Interscience Conference of Antimicrobial Agents and...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.